- Home
- SLN vs OCGN Comparison
SLN vs OCGN Comparison
Compare SLN & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- OCGN
- Stock Information
- Founded
- SLN 1994
- OCGN 2013
- Country
- SLN United Kingdom
- OCGN United States
- Employees
- SLN N/A
- OCGN N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLN Health Care
- OCGN Health Care
- Exchange
- SLN Nasdaq
- OCGN Nasdaq
- Market Cap
- SLN 299.4M
- OCGN 283.3M
- IPO Year
- SLN N/A
- OCGN N/A
- Fundamental
- Price
- SLN $5.04
- OCGN $1.00
- Analyst Decision
- SLN Buy
- OCGN Strong Buy
- Analyst Count
- SLN 5
- OCGN 3
- Target Price
- SLN $32.60
- OCGN $6.00
- AVG Volume (30 Days)
- SLN 77.4K
- OCGN 3.0M
- Earning Date
- SLN 08-07-2025
- OCGN 08-01-2025
- Dividend Yield
- SLN N/A
- OCGN N/A
- EPS Growth
- SLN N/A
- OCGN N/A
- EPS
- SLN N/A
- OCGN N/A
- Revenue
- SLN $27,169,000.00
- OCGN $4,754,000.00
- Revenue This Year
- SLN N/A
- OCGN N/A
- Revenue Next Year
- SLN N/A
- OCGN N/A
- P/E Ratio
- SLN N/A
- OCGN N/A
- Revenue Growth
- SLN 20.09
- OCGN N/A
- 52 Week Low
- SLN $1.97
- OCGN $0.52
- 52 Week High
- SLN $20.48
- OCGN $1.40
- Technical
- Relative Strength Index (RSI)
- SLN 33.31
- OCGN 47.32
- Support Level
- SLN $4.86
- OCGN $0.93
- Resistance Level
- SLN $6.40
- OCGN $1.11
- Average True Range (ATR)
- SLN 0.45
- OCGN 0.06
- MACD
- SLN -0.15
- OCGN -0.01
- Stochastic Oscillator
- SLN 10.92
- OCGN 27.07
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").